Rheumatoid arthritis (RA) is a disease where the immune system attacks the linings of the joints, resulting in joint pain, stiffness, swelling, and destruction. Although many products are available for the treatment of RA, limitations such as adverse reactions and tolerance greatly affect adherence. Many of the current biologic disease-modifying antirheumatic drugs on the market are injectables, leaving a void to be filled for a product that can be taken orally. The most advanced of these approaches, the Janus kinase (JAK) inhibitors, are oral drugs that have not only made a breakthrough in RA, but also other skin conditions.
SinghJASaagKGBridgesSLet al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2015;68(1):1-25. doi:10.1002/acr.22783.
NakayamadaSKuboSIwataSet al. Recent progress in JAK inhibitors for the treatment of rheumatoid arthritis. BioDrugs. 2016;30(5):407-419.
4.
StrandVKremerJMGrubenDet al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res. 2017;69(4):592-598. doi:10.1002/acr.23004
5.
DougadosMVanHDChenYCet al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88-95. doi:10.1136/annrheumdis-2016-210094.
6.
VanhoutteFMazurMVoloshynOet al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Annals of the Rheumatic Diseases. 2017;76:998-1008.
